COMMUNIQUÉS West-GlobeNewswire

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
22/04/2025
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Best Female Libido Boosters 2025 and Sexual Enhancement Pills for Women - By Oh Yes
22/04/2025
Rhyl, Wales, April 22, 2025 (GLOBE NEWSWIRE) -- A healthy sex life plays an important role in a woman's relationships, mental health, and confidence. However, nearly 1 in 3 women have sexual problems that can erode [...]
Aveanna to Participate at the Bank of America Securities 2025 Health Care Conference
22/04/2025
ATLANTA, April 22, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Bank of America Securities 2025 Health Care Conference in [...]
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
22/04/2025
Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT ™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including [...]
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
22/04/2025
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it [...]
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
22/04/2025
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic [...]
Transactions in Connection with Share Buy-back Program
22/04/2025
Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
22/04/2025
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
22/04/2025
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel [...]
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
22/04/2025
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
22/04/2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. [...]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
22/04/2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
22/04/2025
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses pacemaker-indicated [...]
Rapport Therapeutics to Participate in Upcoming Investor Conferences
22/04/2025
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
22/04/2025
TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
PolyPid to Participate in The Citizens Life Sciences Conference
22/04/2025
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s [...]
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
22/04/2025
Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical [...]
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
22/04/2025
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical [...]
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22/04/2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has [...]

Pages